CYP2C9 and thyroid cancer: Eight metabolism related genes including HMGCL, HMGCS1, CYP39A1, CYP2C9, CYP2E1, CYP2J2, CYP2S1, and CSGLCA-T have been screened to be potential synthetic lethal partners of BRAFV600E in melanomas, and HMGCL was finally validated as a synthetic lethal target of BRAFV600E.7 Similar to melanomas, there is a high prevalence of BRAFV600E mutation in thyroid cancers.14,15 Thus, we first analyzed the expression of these eight genes in PTCs from TCGA database.